Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
McKesson
Boehringer Ingelheim
Dow
AstraZeneca

Last Updated: August 17, 2022

Claims for Patent: 6,613,308


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 6,613,308
Title: Pulmonary delivery in treating disorders of the central nervous system
Abstract:A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. The drug is administered at a dose which is at least about two-fold less than the dose required by oral administration. Particles that include the drug can be employed. Preferred particles have a tap density of less than about 0.4 g/cm.sup.3. In addition to the medicament, the particles can include other materials such as, for example, phospholipids, amino acids, combinations thereof and others.
Inventor(s): Bartus; Raymond T. (Sudbury, MA), Emerich; Dwaine F. (Cranston, RI)
Assignee: Advanced Inhalation Research, Inc. (Cambridge, MA)
Application Number:09/877,734
Patent Claims: 1. A method for treating Parkinson's disease comprising administering to the respiratory tract of a patient in need of treatment or rescue therapy a drug for treating Parkinson's disease wherein the drug is administered in a dose that is at least about two times less than that required by oral administration and wherein delivery is to the pulmonary system.

2. The method of claim 1 wherein the drug is levodopa.

3. The method of claim 1 wherein the dose is between about two times and about five times less than that required by oral administration.

4. The method of claim 1 wherein the dose is between about two times and about ten times less than that required by oral administration.

5. The method of claim 1 wherein delivery is to the alveoli region of the pulmonary system.

6. The method of claim 1 wherein administering is for rescue therapy.

7. The method of claim 1 wherein administering is during ongoing treatment.

8. The method of claim 1 wherein the drug is present in dry powder particles.

9. The method of claim 8 wherein the drug is present in the dry powder particles in an amount of at least 20 weight percent in the drug containing particles.

10. The method of claim 8 wherein the drug is present in the dry powder particles in an amount of at least 40 weight percent in the drug containing particles.

11. The method of claim 8 wherein the drug is present in the dry powder particles in an amount of at least 50 weight percent in the drug containing particles.

12. The method of claim 8 wherein the particles have a tap density of less than about 0.4 g/cm.sup.3.

13. The method of claim 8 wherein the particles have a mass median aerodynamic diameter of less than about 5 microns.

14. The method of claim 8 wherein the particles have a mass median geometric diameter greater than about 5 microns.

15. The method of claim 8 wherein the particles have a mass median aerodynamic diameter of less than about 3 microns.

16. The method of claim 8 wherein the particles include a phospholipid.

17. The method of claim 8 wherein the particles include a multivalent salt.

18. The method of claim 8 wherein the particles are administered via a dry powder inhaler.

19. The method of claim 18 wherein the dry powder inhaler is a single dose breath activated dry powder inhaler.

20. The method of claim 1 further comprising co-administering at least one additional agent wherein the drug and the agent are present in the same formulation.

21. The method of claim 1 further comprising co-administering at least one additional agent wherein the drug and the agent are separately formulated.

22. The method of claim 21 wherein the drug and the agent are blended together into a receptacle.

23. The method of claim 21 wherein the drug and the agent are administered sequentially.

24. The method of claim 1 further comprising co-administering at least one additional agent wherein the additional agent is administered by conventional therapies.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
McKinsey
Medtronic
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.